News from IVAC

June 2018

Commentary: The Ideal Community of Practice—Engaging Local Stakeholders in Uganda to Develop Cost of Illness Estimates and Beyond

As part of the Decade of Vaccine Economics (DOVE) project’s phase IV, researchers from the International Vaccine Access Center at Johns Hopkins University (IVAC) and Makerere University School of Public Health (MAKSPH) have teamed up to measure cost of illness estimates for pneumonia, diarrhea and measles in children under-five in Uganda and Bangladesh. The study has been implemented in four districts in Uganda (Gulu, Jinja, Mbarara and Wakiso districts) and two divisions in Bangladesh (Sylhet and Rajshahi divisions), from July 2017 to August 2018.

Read More >
April 2018

IVAC Welcomes Dr. Naor Bar-Zeev

The International Vaccine Access Center (IVAC) is pleased to announce that Naor Bar-Zeev, MBBS(Hons), MPH, MBiostat, PhD, has joined the IVAC team as an Associate Professor in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health.

Read More >
March 2018

Commentary: The new typhoid conjugate vaccine marks the dawn of a unique beginning

The news on the prequalification of Typhoid Conjugate Vaccine by the World Health Organization on January 3rd, 2018 and endowment by Gavi have dawned a unique beginning for the entire field of public health. For the first time, a vaccine has been prequalified by WHO that is only needed in the routine immunization programs of of low and middle- income countries in South Asia and Africa.

Read More >
March 2018

Commentary: IVAC’s Newest Mission: Championing Adult Vaccination

Young children and older adults are both at higher risk for potentially devastating and debilitating diseases, many of which are vaccine-preventable. A large portion of countries have failed to address vaccine-preventable diseases like influenza, pneumococcal disease, and herpes zoster (shingles), which affect this fast-growing demographic.

Read More >